StreetInsider.com News Articles

Izotropic closes $150,000 private placement financing

Tue, 06 Oct 2026 08:01:11 -0400

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) has completed a non-brokered private placement, issuing 750,000 units at $0.20 per unit for gross proceeds of $150,000, according to a company statement.

Each unit consists of one common share and one transferable warrant. Each warrant allows the holder to purchase one additional share at $0.30 for a period of three years from the closing of the offering.

The company said proceeds will be used for general working capital. All securities issued are subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable

Izotropic closes $150,000 private placement financing

Tue, 06 Oct 2026 08:01:11 -0400

Izotropic Closes Non-Brokered Private Placement

Tue, 06 Oct 2026 08:00:00 -0400

Vancouver, British Columbia and Casablanca, Morocco--(Newsfile Corp. - October 6, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that further to its September 25^th announcement it has completed a non-brokered private placement financing (the "Offering"), whereby the Company issued 750,000 units (each, a "Unit") at a price of $0.20 per Unit for gross proceeds of $150,000.

Each Unit consists of one common share and one transferable warrant (each, a

Izotropic Closes Non-Brokered Private Placement

Tue, 06 Oct 2026 08:00:00 -0400

Each Unit consists of one common share and one transferable warrant (each, a

Izotropic Closes Non-Brokered Private Placement

Tue, 06 Oct 2026 08:00:00 -0400

Each Unit consists of one common share and one transferable warrant (each, a

Izotropic Closes Non-Brokered Private Placement

Tue, 06 Oct 2026 08:00:00 -0400

Each Unit consists of one common share and one transferable warrant (each, a

Izotropic plans $150K private placement at $0.20 per unit

Fri, 25 Sep 2026 08:01:10 -0400

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced plans to complete a non-brokered private placement of 750,000 units with a strategic investor at $0.20 per unit, for gross proceeds of up to $150,000.

Each unit consists of one common share and one transferable warrant. Each warrant entitles the holder to purchase one additional share at $0.30 for a period of three years from the closing of the offering.

The company stated that proceeds will be used for general working capital. All securities issued will be subject to a statutory hold period of four months and one day from the date of

Izotropic plans $150K private placement at $0.20 per unit

Fri, 25 Sep 2026 08:01:10 -0400

The company stated that proceeds will be used for general working capital. All securities issued will be subject to a statutory hold period of four months and one day from the date of

Izotropic Announces Non-Brokered Private Placement

Fri, 25 Sep 2026 08:00:00 -0400

Vancouver, British Columbia and Casablanca, Morocco--(Newsfile Corp. - September 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces the intention to complete a non-brokered private placement (the "Offering") with of 750,000 units of the Company with a strategic investor, (each a "Unit") at a price of $0.20 per each Unit for gross proceeds of up to $150K. Each Unit will consist of one common share and one transferable Warrant (each, a

Izotropic Announces Non-Brokered Private Placement

Fri, 25 Sep 2026 08:00:00 -0400

Izotropic Announces Non-Brokered Private Placement

Fri, 25 Sep 2026 08:00:00 -0400

Izotropic Announces Non-Brokered Private Placement

Fri, 25 Sep 2026 08:00:00 -0400

Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCC

Thu, 02 Jul 2026 08:00:00 -0400

Vancouver, British Columbia and Casablanca, Morocco--(Newsfile Corp. - July 2, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that, further to its April 29, 2026 announcement, it has executed the Formal Agreement (the "Formal Agreement") with Izotropic Africa ("IZAF"), together with the Distribution Agreement and Shareholders' Agreement, establishing the definitive commercial, operational, and governance framework for the commercialization of IzoView throughout Africa and the Gulf Cooperation Council ("GCC") (collectively,

Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCC

Thu, 02 Jul 2026 08:00:00 -0400

Izotropic Africa Launches Operations in Casablanca

Wed, 29 Apr 2026 08:00:00 -0400

Vancouver, British Columbia and Casablanca, Morocco--(Newsfile Corp. - April 29, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces the official launch of Izotropic Africa in Casablanca, Morocco, and the appointment of Mr. Mohammed Sair as General Manager.

Advancing Regional Operations and Market Deployment Across Africa and the GCC

Izotropic Africa will operate across 38 African countries and the GCC countries (Saudi Arabia, UAE, Qatar, Kuwait, Oman, and Bahrain) and is supported

Izotropic Africa Launches Operations in Casablanca

Wed, 29 Apr 2026 08:00:00 -0400

Advancing Regional Operations and Market Deployment Across Africa and the GCC

Izotropic Africa will operate across 38 African countries and the GCC countries (Saudi Arabia, UAE, Qatar, Kuwait, Oman, and Bahrain) and is supported

Izotropic Announces Debt Settlement

Tue, 21 Apr 2026 14:09:00 -0400

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 21, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a debt settlement agreement (the "Agreement") with a lender (the "Lender") to settle a portion of the principal balance pursuant to a promissory note originally issued by the Company.

The Company previously entered into a promissory note dated April 1, 2022, with the Lender in the principal amount of

Izotropic Announces Debt Settlement

Tue, 21 Apr 2026 14:09:00 -0400

The Company previously entered into a promissory note dated April 1, 2022, with the Lender in the principal amount of

Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health

Wed, 25 Feb 2026 08:00:00 -0400

Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - February 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that, further to its February 18th announcement regarding the formation "Izotropic Africa" under a Letter Agreement, the proposed Casablanca-based entity has entered into partnership discussions with the Mohammed VI Foundation for Science & Health ("FM6SS"). The FM6SS operates as a public utility institution under the patronage of King Mohammed VI,

Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health

Wed, 25 Feb 2026 08:00:00 -0400

Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC

Wed, 18 Feb 2026 08:00:00 -0400

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 18, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a Letter Agreement (the "Agreement") with a business group ("BG") to establish an entity named Izotropic Africa (the "Entity") based in Casablanca, Morocco. The Entity is intended to license, market, distribute, and evaluate manufacturing and/or assembly of IzoView Breast CT and certain follow-on products in all of Africa

Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC

Wed, 18 Feb 2026 08:00:00 -0400

Izotropic completes $300,000 private placement and settles debt

Wed, 04 Feb 2026 08:02:16 -0400

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) completed a non-brokered private placement raising $300,000 and entered into a debt settlement agreement with a lender, according to a company statement.

The medical device company issued 1,200,000 units at $0.25 per unit. Each unit consists of one common share and one transferable warrant that allows the holder to purchase an additional share at $0.25 for three years from the closing date.

The company will use proceeds from the offering for general working capital purposes.

Separately, Izotropic settled $60,000 in accrued interest owed to a lender through the issuance of 240,000 units at $0.25 per

Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement

Wed, 04 Feb 2026 08:00:00 -0400

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 4, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its January 28, 2026 announcement it has completed a non-brokered private placement financing (the "Offering"), and that is has entered into a debt settlement agreement (the "Agreement") with a lender (the "Lender") to settle outstanding interest payable pursuant to a promissory note originally issued by the Company.

In connection with

Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement

Wed, 04 Feb 2026 08:00:00 -0400

In connection with